

Confidential

Date and Time: Wednesday 24 October 2012, 1000 - 1630

Minutes: Confirmed

**Guideline Development Group Meeting Management of ulcerative colitis
12**

Place: *Royal Institute of British Architects, 66 Portland Place, London W1B
1AD*

Present: Alan Lobo, Consultant Physician & Gastroenterologist (GDG Chair)
David Bartolo, Consultant Colorectal Surgeon
Sarah Cripps, Gastroenterology Pharmacist
Valda Forbes, Gastroenterology & Hepatology Clinical Nurse Specialist
Adam Harris, Consultant Physician & Gastroenterologist
Jeremy Nightingale, Consultant Physician & Gastroenterologist
Kerry Robinson, IBD Clinical Nurse Specialist
Eshan Senanayake, General Practitioner
Nigel Westwood, Patient member (not present for item 6)
Kate Kelley, Associate Director, NCGC
Amelia Ch'ng, Project Manager, NCGC (notes)
Rachel Wheeler, Research Fellow, NCGC
Lola Adedokun, Health Economist, NCGC
Ralph Hughes, Senior Health Economist, NCGC

Apologies: Assad Butt, Consultant Paediatrician in Gastroenterology & Nutrition
Bernard Higgins, Clinical Director, NCGC
Paul Miller, Senior Information Scientist, NCGC

In attendance:

NICE Staff:		
NICE attendee 1	Clifford Middleton, Guidelines Commissioning Manager (present for items 1-6)	
NICE attendee 2	Lyn Knott, Senior Medical Editor	
NICE attendee 3	David Tyldesley, Senior Costing Analyst	

Observers:

--	--	--

Notes

Notes

1. **Welcome and declarations of interest**

The Chair welcomed the group to the twelfth meeting of this guideline development group. David Tyldesley was welcomed to the meeting; DT is the NICE costings lead for the guideline.

The Chair reviewed the declarations of interest register and noted that NW would need to leave the room when the recommendations on induction and maintenance were discussed due to previously declared personal pecuniary interests.

The Chair requested updates to the declarations of interest register. SC advised she will be speaking at the national UKCPA autumn symposium on 16 November 2012, and will receive conference fees, travel and accommodation. The symposium is funded by various drug companies: Napp; Sanofi; Pfizer; Hameln; RPS. The Chair agreed that this does not represent a conflict of interest therefore no action was required. JN advised he will be giving a talk in one month on nutrition and will receive a speaker's fee from Abbott. Abbott manufactures adalimumab which is not under consideration therefore no conflict of interest exists. No other new declarations were received from GDG members and therefore no further action was required.

Apologies were received from AB.

2. **GDG11 NICE minutes**

The minutes of the last meeting of this group were agreed as a true and accurate account of the meeting.

3. **Maintenance model**

The GDG reviewed the results of the maintenance health economic model.

4. **Role of the NICE costings lead**

The GDG was given a presentation on the role of the NICE costings lead and how the work of the costings team facilitates implementation of the guideline.

5. **Future research recommendations**

The GDG agreed the five high-priority future research recommendations.

6. **Draft recommendations/LETRs**

The GDG agreed the draft recommendations and link to the evidence.

7. **Key priorities for implementation**

Due to time restrictions this item was not discussed and will be agreed outside of the meeting.

8. **Any other business**

The next meeting is the final meeting of this guideline development group.

Date, time and venue of the next meeting

Friday 15 March 2013, from 1000 until 1600.

Boardroom, NCGC, 180 Great Portland Street, London W1W 5QZ